| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MED | Common Stock | Award | $0 | +16,486 | +35% | $0.000000 | 63,614 | 14 Feb 2024 | Direct | F1 |
| transaction | MED | Common Stock | Tax liability | $288,212 | -5,471 | -8.6% | $52.68 | 58,143 | 14 Feb 2024 | Direct | |
| holding | MED | Common Stock | 108,598 | 14 Feb 2024 | The Dan and Allyson Family Irrevocable Trust | F2 |
| Id | Content |
|---|---|
| F1 | 8,243 Performance Stock Units were granted on March 17, 2021, and vested on December 31, 2023 and converted into common stock on a two-for-one basis due to the achievement of certain performance factors. The Compensation Committee of the Medifast Board of Directors approved the performance factors on February 14, 2024 and the shares were released on February 14, 2024. |
| F2 | These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. |